Allunan Rosucard: umarnin don amfani da sake dubawa game da miyagun ƙwayoyi

Babban sinadaran aiki na Rosucard shine rosuvastatin. Yawancin tasirin miyagun ƙwayoyi yana faruwa a cikin hanta - babban sashin jiki don haɗin cholesterol. Rosucard yana saukar da matakin lipoproteins mai yawa (LDL), watau "mummunan" cholesterol kuma yana haɓaka matakin "mai kyau" cholesterol (HDL - high lienspropoins).

Mako guda bayan fara shan Rosucard, an lura da ingantaccen tasirin warkewa. Ana iya samun ci gaba mafi girma a makonni biyu bayan fara magani tare da Rosucard. Don cimma sakamako mai ɗorewa, hanya ta lura ya kamata aƙalla wata ɗaya.

Alamu don amfanin Rosucard sune:

na farko hypercholesterolemia,
Ciki mai yalwar cuta,
maganin rashin lafiyar,
atherosclerosis.

Hakanan, an wajabta maganin don hana ci gaban cututtukan zuciya a cikin marasa lafiya da ke cikin haɗari.

Wani fasalin amfani da Rosucard shine cewa kafin fara shan maganin, mai haƙuri dole ne ya fara biye da ƙarancin kalori da kuma bin ta a duk tsawon lokacin magani. Dangane da umarnin, ana iya ɗaukar Rosucard a kowane lokaci na rana, ba tare da la'akari da cin abincin ba.

An zaɓi kashi na miyagun ƙwayoyi ta likita daban-daban, la'akari da makasudin da halayen haƙuri. A mafi yawan lokuta, kashi na farko na Rosucard shine 10 MG. Bayan wata daya, ana iya ƙara zuwa 20 MG. A cikin mawuyacin lokuta mawuyacin hali, an tsara 40 mg na Rosucard An sanya maganin a cikin yara 'yan kasa da shekaru 10.

Yayin aiwatar da shan Rosucard, za'a iya lura da wasu sakamako masu illa. Don haka a kan tsananin bayansa da ciwon kai, rashin jin daɗi daga cututtukan gastrointestinal, wato ciki na ciki, tashin zuciya, maƙarƙashiya, amai da rashin lafiyar, ana yawan lura da su. Mai tsananin wahalar cuta ce ta rashin bacci, haka kuma hanyoyin kumburi a hanta - hepatitis. Sakamakon sakamako na Rosucard, a matsayin mai mulkin, ya dogara da kashi-kashi.

Contraindications don ɗaukar Rosucard sune:

mutum rashin haƙuri,
daban-daban m hanta cututtuka, ciki har da ƙara matakan transaminase,
cutar koda
shan nau'in cyclosporine,
ciki da lactation,
myopathies.

Tare da kulawa ta musamman, an wajabta Rosucard ga marasa lafiya na Asiya ko kuma sun girmi shekaru 70, kazalika da maganin cututtukan jini, giya, magani tare da zazzabi da kuma bayan cututtukan tsoka. Lokacin shan Rosucard, mutanen da ke da glucose na jini suna da haɗarin haɓakar ciwon sukari.

A cikin waɗannan nau'ikan masu haƙuri, kafin a rubuta Rosucard, yana da mahimmanci a gwada haɗarin da ke akwai da tasirin warkewar cutar. Lokacin da ake rubuta musu magungunan, ana bada shawarar a gudanar da magani a asibiti a karkashin kulawar likitoci.

Kafin fara aikin jiyya tare da Rosucard, an gargadi marasa lafiya game da buƙatar sanar da likita mai halartar game da bayyanar ciwon tsoka, cramps, rauni, musamman tare da malaise na gaba da hauhawar jini. An yanke shawarar soke ko ci gaba da shan miyagun ƙwayoyi akan bayanan dakin gwaje-gwaje.

Analogs na Rosucard

Yayi daidai da alamun

Farashin daga 54 rubles. Analog mai rahusa ne ta hanyar 811 rubles

Yayi daidai da alamun

Farashi daga 324 rubles. Analog ne mai rahusa ta hanyar 541 rubles

Yayi daidai da alamun

Farashin daga 345 rubles. Analog ɗin yana da rahusa ta 520 rubles

Yayi daidai da alamun

Farashin daga 369 rubles. Analog ne mai rahusa ta hanyar 496 rubles

Yayi daidai da alamun

Farashin daga 418 rubles. Analog ne mai rahusa ta hanyar 447 rubles

Yayi daidai da alamun

Farashin daga 438 rubles. Analog ne mai rahusa ta hanyar 427 rubles

Yayi daidai da alamun

Farashin daga 604 rubles. Analog ne mai rahusa ta hanyar 261 rubles

Yayi daidai da alamun

Farashin daga 660 rubles. Analog ne mai rahusa ta 205 rubles

Yayi daidai da alamun

Farashin daga 737 rubles. Analog ne mai rahusa ta hanyar 128 rubles

Tsarin saki, abun da aka shirya da marufi

Allunan mai rufe fim ruwan hoda mai haske, oblong, biconvex, tare da haɗari.

Shafin 1
alli na rosuvastatin	10.4 mg
wanda ya dace da abin da ke cikin rosuvastatin	10 MG

Wadanda suka kware: lactose monohydrate - 60 mg, microcrystalline cellulose - 45.4 mg, croscarmellose sodium - 1.2 mg, colloidal silicon dioxide - 600 μg, magnesium stearate - 2.4 mg.

Tsarin fim ɗin harsashi: hypromellose 2910/5 - 2.5 mg, macrogol 6000 - 400 μg, titanium dioxide - 325 μg, talc - 475 μg, baƙin ƙarfe jan ƙarfe oxide - 13 μg.

10 inji mai kwakwalwa. - blister (3) - fakitoci na kwali.
10 inji mai kwakwalwa. - blister (6) - fakitoci na kwali.
10 inji mai kwakwalwa. - blister (9) - fakitoci na kwali.

Aikin magunguna

Magungunan ƙwayar cuta daga rukunin gumakan. Zabi mai hana ingila na HMG-CoA reductase, mai samar da enzyme wanda ke canza HMG-CoA zuwa mevalonate, mai keratin cholesterol (Ch).

Theara yawan masu karɓar LDL a saman hepatocytes, wanda ke haifar da karuwar haɓakawa da catabolism na LDL, hanawar haɗakar VLDL, rage yawan haɗakar LDL da VLDL. Rage yawan taro na LDL-C, HDL cholesterol-non-lipoproteins (HDL-wadanda ba HDL), HDL-V, Xc, TG, TG-VLDL, apolipoprotein B (ApoV), sun rage yawan rabo na LDL-C / Lc-HDL, jimlar Xc / XL HDL-C, Chs-not HDL-C / HDL-C, ApoB / apolipoprotein A-1 (ApoA-1), yana kara yawan kwarin gwiwar HDL-C da ApoA-1.

Tebur 1. Sakamakon-kashi dogaro a cikin marasa lafiya da keɓaɓɓen hypercholesterolemia (nau'in IIa da IIb gwargwadon rarrabuwa da Fredrickson) (matsakaiciyar sauyin da aka daidaita sau ɗaya idan aka kwatanta da ƙimar farko)

Kashi	Yawan marasa lafiya	HS-LDL	Jimlar Chs	HS-HDL
Waka	13	-7	-5	3
10 MG	17	-52	-36	14
20 MG	17	-55	-40	8
40 MG	18	-63	-46	10
Kashi	Yawan marasa lafiya	TG	Xc- wadanda ba HDL ba	Apo v	Apo AI
Waka	13	-3	-7	-3	0
10 MG	17	-10	-48	-42	4
20 MG	17	-23	-51	-46	5
40 MG	18	-28	-60	-54	0

Tebur 2. Sakamakon-kashi-mai-ƙarfi a cikin marasa lafiya da ke ɗauke da cututtukan jini (nau'in IIb da na IV bisa ga ƙididdigar Fredrickson) (ƙimar matsakaicin ƙaranci idan aka kwatanta da ƙimar farko)

Kashi	Yawan marasa lafiya	TG	HS-LDL	Jimlar Chs
Waka	26	1	5	1
10 MG	23	-37	-45	-40
20 MG	27	-37	-31	-34
40 MG	25	-43	-43	-40
Kashi	Yawan marasa lafiya	HS-HDL	Xc- wadanda ba HDL ba	Xc- VLDL	TG- VLDL
Waka	26	-3	2	2	6
10 MG	23	8	-49	-48	-39
20 MG	27	22	-43	-49	-40
40 MG	25	17	-51	-56	-48

Ingancin asibiti

Inganci a cikin marasa lafiyar manya tare da hypercholesterolemia tare da ko ba tare da hypertriglyceridemia ba, ba tare da la'akari da launin fata, jinsi ko shekaru ba, incl. a cikin marasa lafiya da ciwon sukari mellitus da familial hypercholesterolemia. A cikin 80% na marasa lafiya tare da nau'in IIa da IIb hypercholesterolemia (bisa ga rarrabuwa na Fredrickson) tare da matsakaicin farawa na LDL-C game da 4.8 mmol / L, yayin ɗaukar ƙwayar a cikin kashi 10 MG, maida hankali ne na LDL-C ya kai ƙasa da 3 mmol / L.

A cikin marasa lafiya tare da heterozygous familial hypercholesterolemia suna karɓar rosuvastatin a kashi 20-80 mg / rana, an lura da ingantaccen tasiri na bayanan lipid. Bayan titration zuwa kashi na yau da kullun na 40 MG (makonni 12 na jiyya), an lura da rage yawan LDL-C ta 53%. A cikin 33% na marasa lafiya, an cimma daidaituwa na LDL-C da ƙasa da 3 mmol / L.

A cikin marasa lafiya tare da hyzycholesterolemia na homozygous familial na karɓar rosuvastatin a kashi 20 MG da 40 MG, matsakaicin raguwa a cikin taro na LDL-C ya kasance 22%.

A cikin marasa lafiya tare da hypertriglyceridemia tare da maida hankali na farko na TG daga 273 mg / dL zuwa 817 mg / dL, karɓar rosuvastatin a cikin allurai na 5 MG zuwa 40 MG 1 lokaci / rana don makonni 6, an rage yawan yawan TG a cikin jini jini (duba tebur 2 )

Ana lura da sakamako mai ƙari a hade tare da fenofibrate dangane da taro na TG kuma tare da acid nicotinic acid a cikin rage ƙwayar lipid (fiye da 1 g / rana) dangane da maida hankali kan HDL-C.

A cikin binciken METEOR, rosuvastatin farjin a hankali ya rage yawan ci gaba na matsakaicin matsakaiciyar ƙwayar intima-media (TCIM) don kashi 12 na ƙwayar carotid idan aka kwatanta da placebo. Idan aka kwatanta da ƙididdigar tushe a cikin rukunin rosuvastatin, an lura da raguwa a cikin mafi girman TCIM ta 0.0014 mm / shekara idan aka kwatanta da haɓaka wannan mai nuna ta 0.0131 mm / shekara a cikin rukunin placebo. Zuwa yau, dangantakar kai tsaye tsakanin raguwa a cikin TCIM da raguwa a cikin haɗarin haɗarin jijiyoyin zuciya ba a nuna su ba.

Sakamakon binciken na JUPITER ya nuna cewa rosuvastatin ya rage haɗarin ci gaba da rikice-rikice na zuciya tare da rage haɗarin dangi na 44%. An lura da tasirin magani bayan farkon watanni 6 na amfani da miyagun ƙwayoyi. An sami raguwar ƙididdigar yawan kashi 48% cikin haɗuwa, ciki har da mutuwa daga cututtukan zuciya, bugun jini da infarction myocardial, raguwar 54% a cikin abin da ya faru na rashin ƙarfi ko rashin haihuwa mai rauni, da kuma 48% ragewa a cikin rauni mai rauni ko maras rai. Gabaɗaya yawan mace-mace ya ragu da 20% a cikin rukunin rosuvastatin. Bayanan martaba a cikin marasa lafiya da ke ɗaukar rosuvastatin 20 MG sun kasance daidai da bayanin martabar aminci a cikin rukunin placebo.

Pharmacokinetics

Bayan shan maganin a cikin C_max Yana isa rosavastatin plasma a cikin awanni 5. Yayyana cikakken bioavailability kusan 20%.

Yin jingina ga ƙwayoyin plasma (galibi tare da albumin) kusan 90%. V_d - 134 l.

Rosuvastatin ne yake yawanci ta hanta, wanda shine babban shafin yanar gizo don haɓakar Chs da metabolism na Chs-LDL.

Har ila yau, ya shiga cikin hanyar shinge.

Biotransformed a cikin hanta zuwa karamin gwargwado (game da 10%), kasancewa mai ba da madaidaicin canji don isoenzymes na tsarin cytochrome P450.

Babban isoenzyme wanda ya shiga cikin metabolism na rosuvastatin shine CINP2C9 isoenzyme. Isoenzymes CYP2C19, CYP3A4 da CYP2D6 ba su da yawa a cikin metabolism.

Babban metabolites na rosuvastatin sune N-dismethyl da lactone metabolites. N-dismethyl kusan 50% ba shi da aiki fiye da rosuvastatin, metabolites lactone ba su da magani. Fiye da 90% na aikin magunguna don hana rarraba HMG-CoA reductase an bayar dashi ta rosuvastatin, sauran sune metabolites.

Kamar yadda yake game da sauran hanawar HMG-CoA reductase inhibitors, wani daskararren membrane yana shiga cikin aiwatar da haɓakar hepatic na maganin - polypeptide yana jigilar kwayoyin anion (OATP) 1B1, wanda ke taka muhimmiyar rawa a cikin kawar da hepatic.

T_1/2 - kimanin sa'o'i 19, ba ya canzawa tare da ƙaruwa da yawa. Matsakaicin aikin plasma shine kusan 50 l / h (yana da banbancin bambanci 21.7%). Kusan 90% na kashi na rosuvastatin an kebe shi ba tare da canzawa ba ta hanyar hanjin cikin, sauran ta hanyar kodan.

Tsarin bayyanar rosuvastatin yana ƙaruwa daidai gwargwado.

Ma'aikatan Pharmacokinetic ba su canzawa tare da amfanin yau da kullun.

Pharmacokinetics a cikin lokuta na musamman na asibiti

A cikin marasa lafiya da ke fama da gazawar ƙarancin ƙayyadadden matsakaici, matsakaici, ƙwayar plasma na rosuvastatin ko N-dysmethyl ba ta canza sosai. A cikin marasa lafiya da ƙarancin rashin ƙarfi na renal (CC kasa da 30 ml / min), maida hankali ne rosuvastatin a cikin jini na jini ya ninka sau 3, kuma N-dismethyl ya ninka har sau 9 sama da na masu sa kai na lafiya. Yawan plasma na rosuvastatin a cikin marasa lafiya akan hemodialysis shine kusan 50% mafi girma fiye da masu taimako na lafiya.

A cikin marasa lafiya da ke fama da rauni na hanta na maki 7 ko ƙananan kan sikelin Yara-Pugh, babu karuwa a cikin T_1/2 rosuvastatin, a cikin marasa lafiya da raunin aikin hanta 8 da 9 akan sikelin Yara-Pugh, an lura da elongation na T_1/2 Sau 2. Babu wani gogewa game da amfani da miyagun ƙwayoyi a cikin marasa lafiya da mummunan rauni na aikin hanta.

Jinsi da tsufa ba su da tasiri mai mahimmanci a asibiti kan magunguna na rosuvastatin.

Sigogi na pharmacokinetic na rosuvastatin sun dogara da tsere. Kungiyar AUC ta wakilan tseren Mongoloid (Jafananci, Sinanci, Filipinos, Vietnamese da Koreans) ya ninka 2 na tseren Caucasian. Indiya matsakaita AUC da C_max karuwa da sau 1.3.

HMG-CoA reductase inhibitors, hade da rosuvastatin yana ɗaure zuwa sunadaran jigilar OATP1B1 (polypeptide na jigilar kwayoyin halitta na kwayoyin halitta wanda ke da hannu cikin ɗimbin hepatocyte na statins) da kuma BCRP (jigilar jigilar mutane). Masu ɗaukar hoto na genotypes SLCO1B1 (OATP1B1) s.521CC da ABCG2 (BCRP) s.421AA sun nuna karuwa a fallasa (AUC) zuwa rosuvastatin 1.6 da 2.4, bi da bi, idan aka kwatanta da masu ɗaukar hoto na genotypes SLCO1B1 s.521TT da ABCG2 s.421CC.

- hypercholesterolemia na farko (nau'in IIa a cewar Fredrickson), wanda ya hada da famteal heterozygous hypercholesterolemia ko hadewar hypercholesterolemia (nau'in IIb a cewar Fredrickson) - a matsayin ƙari ga abincin, lokacin cin abinci da sauran hanyoyin magani marasa magani (alal misali, motsa jiki na jiki, asarar nauyi) bai isa ba

- hypercholesterolemia na gidan homozygous - a matsayin kari ga abinci da sauran hanyoyin rage kiba (alal misali, LDL-apheresis), ko kuma a yanayin da irin wannan maganin bashi da inganci,

- hypertriglyceridemia (nau'in IV a cewar Fredrickson) - a matsayin ƙari ga abincin,

- don sassauta ci gaban atherosclerosis - a matsayin ƙari ga abincin a cikin marasa lafiya waɗanda aka nuna jiyya don rage yawan jimlar Chs da Chs-LDL,

- rigakafin farko na manyan rikice-rikice na jijiyoyin jini (bugun jini, bugun zuciya, farfadowa na jijiya) a cikin marasa lafiya marasa lafiya ba tare da alamun asibiti na cututtukan jijiyoyin zuciya ba, amma tare da ƙara haɗarin ci gabanta (fiye da shekaru 50 na maza da fiye da shekaru 60 na mata, ƙara yawan ƙwayar C-reactive protein (≥ 2 mg / l) a gaban ƙarancin ɗayan ƙarin haɗarin haɗari, kamar hauhawar jijiyoyin jini, ƙananan taro na HDL-C, shan sigari, tarihin dangi na farkon farkon cututtukan zuciya).

Sakawa lokacin

Ana ɗaukar magani a baka. Ya kamata a hadiye allunan gaba daya, ba tare da taunawa ba kuma a murƙushe, a wanke da ruwa, a kowane lokaci na rana, ba tare da la'akari da cin abinci ba.

Kafin farawa da jiyya tare da Rosucard ®, mara lafiya ya kamata ya fara bin daidaitaccen abincin rage kiba da ci gaba da bin sa yayin jiyya.

Ya kamata a zaɓi kashi na miyagun ƙwayoyi daban-daban dangane da alamomi da amsawar warkewa, yin la’akari da shawarwarin da ake yarda da su na yau da kullun game da abubuwan da ke tattare da yawan ƙwayoyin cutar lipid.

Thewarin da aka ba da shawarar farko na Rosucard ® ga marasa lafiya da suka fara shan maganin, ko don marasa lafiya da aka canjawa wuri daga shan sauran hanawar HMG-CoA reductase, shine 5 ko 10 mg 1 lokaci / rana.

Lokacin zaɓin kashi na farko, mutum yakamata ya jagorance shi da abubuwan da ke cikin cholesterol na haƙuri kuma yayi la'akari da haɗarin haɓaka rikice-rikice na zuciya, kuma lallai ne a tantance yiwuwar haɗarin sakamako masu illa. Idan ya cancanta, bayan makonni 4 ana iya ƙara yawan ƙwayoyi.

Sakamakon yiwuwar haɓaka sakamako masu illa yayin ɗaukar miyagun ƙwayoyi a kashi 40 MG, idan aka kwatanta da ƙananan allurai na miyagun ƙwayoyi, ƙaddamarwa ta ƙarshe zuwa matsakaicin adadin 40 MG ya kamata a aiwatar da shi kawai a cikin marasa lafiya da mummunan hypercholesterolemia da haɗarin haɗari na rikicewar zuciya (musamman a cikin marasa lafiya tare da hypercholesterolemia na gado), wanda a lokacin da shan miyagun ƙwayoyi a kashi 20 na MG, ba'a cimma daidaitaccen matakin cholesterol ba. Irin waɗannan marasa lafiya ya kamata su kasance a ƙarƙashin kulawar likita. Musamman saka idanu akan marasa lafiya da suke karbar maganin a cikin kashi 40 MG ana bada shawara.

Ba a bada shawarar sashi na 40 mg ba ga marasa lafiya wadanda basuyi tuntuɓar likita ba. Bayan makonni 2-4 na ilmin likita da / ko tare da karuwa a cikin kashi na Rosucard ®, ya wajaba a kula da metabolism na lipid (gyara kashi ya zama dole idan ya cancanta).

A tsofaffi marasa lafiya fiye da 65 ba a bukatar daidaitawa da kashi.

A marasa lafiya da gazawar hanta tare da dabi'u da ke ƙasa 7 maki kan sikelin-Yara ba a buƙatar daidaita sakin Rosucard.

A marasa lafiya tare da m renal gazawarba a buƙatar daidaita siginar miyagun ƙwayoyi Rosucard ®, ana buƙatar kashi na farko na 5 MG / rana. A marasa lafiya tare da gazawar matsakaici matsakaici (CC 30-60 ml / min) yin amfani da miyagun ƙwayoyi Rosucard ® a kashi 40 na MG / rana yana tazara. A mai tsanani gazawar koda (CC kasa da 30 ml / min) yin amfani da miyagun ƙwayoyi Rosucard ® yana contraindicated.

A marasa lafiya da ke cikin farji don kamuwa da cutar sankara yin amfani da miyagun ƙwayoyi Rosucard ® a kashi 40 na MG / rana yana tazara. Lokacin da aka tsara maganin a cikin allurai na 10 MG da 20 MG / rana, shawarar farko da aka bayar don wannan rukuni na masu haƙuri shine 5 mg / day.

Lokacin da ake nazarin sigogin magunguna na rosuvastatin, an lura da haɓakar ƙwayar magungunan a cikin wakilai. Tsere na Mongoloid. Ya kamata a yi la'akari da wannan gaskiyar yayin rubuta Rosucard ® ga marasa lafiya na tseren Mongoloid. Lokacin da aka tsara magunguna a cikin allurai na 10 MG da 20 MG, shawarar farko da aka bayar don wannan rukuni na marasa lafiya shine 5 MG / rana. Yin amfani da miyagun ƙwayoyi Rosucard ® a kashi 40 na MG / rana a cikin wakilan tseren Mongoloid an hana shi.

Halittar kwayoyin halitta. Masu ɗaukar hoto na genotypes SLCO1B1 (OATP1B1) c.521CC da ABCG2 (BCRP) c.421AA sun nuna karuwa a cikin bayyanar (AUC) na rosuvastatin idan aka kwatanta da masu ɗaukar hoto na genotypes SLC01B1 s.521TT da ABCG2 s.421CC. Ga marasa lafiya da ke ɗauke da genotypes c.521SS ko c.421AA, mafi girman shawarar Rosucard ® shine 20 mg / rana.

Gudanar da aikin kwantar da hankali. Rosuvastatin yana ɗaure wa furotin na sufuri daban-daban (musamman, OATP1B1 da BCRP). Lokacin da aka yi amfani da miyagun ƙwayoyi na Rosucard ® tare da kwayoyi (kamar cyclosporine, wasu masu hana HIV kariya, haɗe da ritonavir tare da atazanavir, lopinavir da / ko tipranavir), wanda ke ƙaruwa da haɗuwa da rosuvastatin a cikin jini na jini saboda hulɗa tare da sunadarai na sufuri, haɗarin myopathy na iya ƙaruwa (gami da rhabdomyolysis). A irin waɗannan halayen, ya kamata ku kimanta yiwuwar rubuta magani na madadin magani ko dakatar da amfani da Rosucard temporarily na ɗan lokaci. Idan amfani da magungunan da ke sama ya zama dole, ya kamata ku fahimci kanku tare da umarnin yin amfani da kwayoyi kafin ku tsara su lokaci ɗaya tare da Rosucard ®, kimanta fa'idar-haɗarin raɗaɗin haɗuwa da la'akari da rage girman Rosucard ®.

Side sakamako

Abubuwan da ke tattare da gefen da aka sani tare da rosuvastatin yawanci suna da sauƙi kuma suna tafiya da kansu. Kamar yadda yake tare da sauran masu hanawa HMG-CoA reductase, hanawar sakamako masu illa sunadarai ne.

Isasan da keɓaɓɓen bayanin martani ne na rosuvastatin, gwargwadon bayanai daga karatun asibiti da kuma ƙwarewar bayan rajista.

Eterayyade yawan tasirin sakamako (rarrabuwa na WHO): sau da yawa (> 1/10), sau da yawa (daga> 1/100 zuwa 1/1000 zuwa 1/10 000 zuwa 20 mg / rana), da wuya - arthralgia, tendopathy, yiwu tare da katsewar jijiyoyi, ba a san mitar ba - immuno-mediated necrotizing myopathy.

Allergic halayen: infrequently - itching fata, urticaria, fitsari, da wuya - maganganun tashin hankali, ciki har da angioedema.

A bangare na fata da kasusuwa na jiki: ba a san mita ba - ciwo na Stevens-Johnson.

Daga tsarin urinary: sau da yawa - proteinuria, mai wuya - hematuria. Canje-canje a cikin adadin furotin a cikin fitsari (daga rashi ko ragi mai yawa zuwa ++ ko fiye) ana lura da ƙarancin 1% na marasa lafiya da suke karɓar kashi 10-20 mg / rana, kuma a kusan 3% na marasa lafiya suna karɓar 40 mg / rana. Proteinuria yana raguwa yayin jiyya kuma baya alaƙa da faruwar cutar koda ko cututtukan urinary fili.

Daga gabobi da mammary gland shine yake: da wuya - gynecomastia.

Manunin dakin gwaje-gwaje: sau da yawa - ƙaruwa-dogara da kashi a cikin aikin CPK aiki (a mafi yawan lokuta, maras muhimmanci, asymptomatic da na ɗan lokaci). Tare da haɓaka fiye da sau 5 idan aka kwatanta da VGN, ya kamata a dakatar da gwaji tare da Rosucard ® na ɗan lokaci. Asedara yawan plasma glycosylated haemoglobin.

Sauran: sau da yawa - asthenia, mita ba a sani ba - na edema yanki.

Lokacin amfani da Rosucard ®, an lura da canje-canje a cikin sigogin gwaje-gwaje masu zuwa: haɓakawa da yawaitar glucose, bilirubin, aikin alkaline phosphatase, da GGT.

Haɓaka halayen masu haɗari masu zuwa an bayar da rahoton su yayin amfani da wasu gumaka: lalatawar datti, yanayin yaɗuwar cutar cututtukan huhu (musamman tare da tsawaita aiki), nau'in ciwon sukari na 2, yawan ci gaban wanda ya danganci kasancewar ko rashin haɗarin abubuwan da ke faruwa (azumin maida hankali ne a cikin jini na 5.6- 6.9 mmol / l, BMI> 30 kilogiram / m 2, hauhawar jini, tarihin hauhawar jini).

Contraindications

Don allunan 10 da 20 MG

- Hypersensitivity ga abubuwan da ke cikin miyagun ƙwayoyi,

- cututtukan hanta a cikin aiki mai aiki ko karuwa a cikin ayyukan hepatic transaminases a cikin magani (fiye da sau 3 idan aka kwatanta da VGN) asalin asali,

- gazawar hanta (tsananin daga maki 7 zuwa 9 akan ma'aunin Yara).

- karuwa cikin taro na CPK a cikin jini sama da sau 5 idan aka kwatanta da VGN,

- matsanancin yanayin aiki na yara (CC kasa da 30 ml / min),

- marasa lafiya sun yi jinkiri ga cigaban rikitarwa,

- gudanar da cyclosporine na lokaci daya,

- hade hade da masu kariya daga kwayar cutar kanjamau,

- cututtukan gado, kamar rashin haƙuri na lactose, rashi lactase ko glucose-galactose malabsorption (saboda kasancewar lactose a cikin abun da ke ciki),

- matan da suka isa haihuwa, wadanda ba sa amfani da hanyoyin isasshen hana haihuwa,

- lactation (shayarwa),

- shekaru har zuwa shekaru 18 (ba a kafa ingantaccen aiki da aminci ba),

Don allunan 40 MG (ban da contraindications na Allunan 10 da 20)

Kasancewar abubuwanda ke tattare da halayen masu zuwa don haɓakar cutar sankarar mahaifa / rhabdomyolysis:

- myotoxicity a bango na yin amfani da sauran masu hana masu HMG-CoA reductase ko fibrates a cikin tarihi,

- gazawar koda na matsakaicin matsakaici (CC 30-60 ml / min),

- yawan shan barasa,

- yanayin da zai iya haifar da karuwa a cikin ƙwayar plasma na rosuvastatin,

- Yawan cin abinci a lokaci daya.

Marasa lafiya na tseren Mongoloid.

Alamar cutar tsoka a cikin tarihin dangi.

Don allunan 10 da 20 MG: tare da tarihin cututtukan hanta, sepsis, hypotension, babbar tiyata, rauni, matsanancin metabolism, endocrine ko electrolyte hargitsi, rikicewar rashin kulawa, tare da sassauci ga matsakaiciyar ƙaddamar da ƙwayar cuta, hypothyroidism, tare da yin amfani da sauran hanawar HMG-CoA reductase inhibitors ko fibrates, alamomi na tarihin yawan ƙwayar tsoka, cututtukan tsoka na gado a cikin anamnesis, tare da gudanar da kulawa na lokaci daya tare da fibrates, yanayin da karuwa a cikin taro kuma rosuvastatin a jini jini a marasa lafiya shekaru fiye da shekaru 65, da Mongoloid tseren marasa lafiya da wuce kima barasa amfani.

Don allunan 40 MG: tare da rauni na koda (CC fiye da 60 ml / min), tarihin cutar hanta, sepsis, hypotension, yawan tasirin tiyata, raunin da ya faru, matsanancin rayuwa, endocrine ko rikicewar electrolyte, raunin da ba a sarrafa shi ba, a cikin marasa lafiya fiye da shekaru 65.

Haihuwa da lactation

Rosucard ® yana a cikin ciki da lactation (nono).

Amfani da Rosucard ® mata masu haihuwazai yiwu ne kawai idan anyi amfani da hanyoyin kariya na aminci kuma idan aka sanar da mara lafiyar game da yiwuwar hadarin magani ga tayin.

Tunda cholesterol da abubuwa da aka haɓaka daga cholesterol suna da mahimmanci don haɓakar tayi, yuwuwar haɗarin hana HMG-CoA ragewa ya wuce amfanin amfani da miyagun ƙwayoyi yayin daukar ciki. Idan an gano ciki yayin maganin tare da miyagun ƙwayoyi, Rosucard ® ya kamata a daina shi nan da nan, kuma ya kamata a faɗakar da mai haƙuri game da haɗarin haɗari ga tayin.

Idan ya zama dole a yi amfani da maganin yayin shayarwa, ba da yiwuwar mummunan al'amura a cikin jarirai ba, ya kamata a magance batun dakatar da shayarwa.

Umarni na musamman

Tasiri akan kodan

A cikin marasa lafiya da ke karɓar ƙwayar ƙwayoyi na rosuvastatin (galibi 40 MG), an lura da tubular proteinuria, wanda a mafi yawancin lokuta na lokaci ne. Irin wannan furotin ba a nuna cutar koda ko ciwan koda ba. A cikin marasa lafiya da ke shan maganin a gwargwadon kashi 40 MG, ana bada shawara don saka idanu akan alamun alamun aiki a lokacin jiyya.

Tasiri akan tsarin musculoskeletal

Lokacin amfani da rosuvastatin a cikin dukkan allurai, kuma musamman a cikin allurai fiye da 20 MG, an ba da rahoton abubuwan da suka biyo baya a kan tsarin musculoskeletal: myalgia, myopathy, a lokuta mafi wuya, rhabdomyolysis.

Eterayyade aikin CPK

Eterayyade aikin CPK bai kamata a aiwatar da shi ba bayan matsanancin ƙoƙari na jiki ko kuma a gaban sauran dalilai masu yiwuwa don haɓaka ayyukan CPK, wanda zai haifar da fassarar da ba ta dace ba game da sakamakon. Idan farkon aikin CPK yana ƙaruwa sosai (sau 5 sama da VGN), bayan kwanaki 5-7, ya kamata a aiwatar da ma'auni na biyu. Bai kamata a fara amfani da shi ba idan gwajin maimaitawa ya tabbatar da farkon ayyukan KFK (fiye da sau 5 sama da VGN).

Kafin farawan magani

Lokacin amfani da Rosucard ®, kamar yadda kuma yayin amfani da sauran hanawar H HC-CoA reductase inhibitors, yakamata a yi taka tsantsan a cikin marasa lafiya tare da halayen haɗari na yanzu don rashin lafiyar ƙwayar cuta / rhabdomyolysis. Ya kamata a tantance rabo mai fa'idar haɗarin, kuma idan ya cancanta, ya kamata a aiwatar da saka idanu akan mara lafiya yayin jiyya.

A lokacin jiyya

Sanar da mara lafiya game da bukatar sanar da likita kai tsaye game da shari'o'in fara jin rauni na tsoka, rauni na tsoka ko gauraya, musamman a hade da zazzabin cizon sauro. A cikin irin waɗannan marasa lafiya, yakamata a ƙayyade aikin CPK. Dole ne a dakatar da aikin idan aikin CPK yana ƙaruwa sosai (fiye da sau 5 sama da VGN) ko kuma idan alamun bayyanar ɓangaren tsokoki suna faɗuwa kuma yana haifar da rashin jin daɗin yau da kullun (koda kuwa aikin KFK bai zama ƙasa da sau 5 idan aka kwatanta da VGN). Idan bayyanar cututtuka ta ɓace, kuma ayyukan CPK sun koma al'ada, ya kamata a ba da kulawa don sake sake rubuta Rosucard ® ko sauran hanawar rage Hase-CoA a cikin ƙananan allurai tare da sa ido sosai a kan mai haƙuri.

Matsayi na yau da kullun game da aikin CPK yayin rashin bayyanar cututtuka ba shi da amfani. Yawancin lokuta na rashin daidaituwa na rigakafi necrotizing myopathy tare da bayyanar asibiti a cikin nau'i na rauni mai ƙarfi na tsokoki mai haɓaka da haɓaka cikin aikin CPK a cikin jijiyoyin jini yayin jiyya ko lokacin ɗaukar mutum-mutumi, gami da rosuvastatin. Ana iya buƙatar ƙarin nazarin ƙwayar tsoka da ƙwayar jijiya, nazarin serological, kazalika da maganin hana daukar ciki. Babu alamun alamun kara yawan jijiyoyin jiki yayin daukar rosuvastatin da maganin kwantar da hankali. Koyaya, an ba da rahoton karuwar cutar myositis da myopathy a cikin marasa lafiya suna ɗaukar wasu hanyoyin hanawa HMG-CoA reductase a hade tare da abubuwan fibric acid, ciki har da gemfibrozil, cyclosporine, nicotinic acid a cikin ƙwayoyin cuta (fiye da 1 g / rana), wakilai mai hana ƙwayoyin cuta, inhibitors, inhibitors Kwayar cutar kwayar cutar kwayar cutar kwayar cutar kwayar cutar kwayar cutar kwayar cutar kwayar cutar kwayar cutar kwayar cutar kwayoyi ne. Gemfibrozil yana kara haɗarin kamuwa da cutar sankarar mahaifa yayin amfani da su tare da wasu masu hana haɓakar rage Hase-CoA. Saboda haka, ba a bada shawarar yin amfani da miyagun ƙwayoyi na Rosucard ® da gemfibrozil lokaci guda ba. Ya kamata a auna raunin haɗari da fa'ida mai amfani a hankali lokacin da aka yi amfani da rosucard together tare da fibrates ko allurai na nicotinic acid. Yin amfani da miyagun ƙwayoyi Rosucard ® a cikin kashi 40 MG tare da fibrates yana contraindicated. Makonni 2-4 bayan fara magani da / ko tare da karuwa a cikin kashi na Rosucard ®, saka idanu na metabolism na lipid ya zama dole (daidaita kashi ya zama dole idan ya cancanta).

An bada shawara don ƙididdigar alamun alamun hanta kafin farawa da kuma watanni 3 bayan farawa. Yin amfani da miyagun ƙwayoyi Rosucard ® ya kamata a dakatar da shi ko ya kamata a rage yawan magungunan idan ayyukan hepatic transaminases a cikin jini na jini ya ninka sau 3 fiye da VGN.

A cikin marasa lafiya tare da hypercholesterolemia saboda hypothyroidism ko ciwo nephrotic, ya kamata a gudanar da maganin manyan cututtuka kafin a yi jiyya tare da Rosucard ®.

Masu hana HIV kariya

Ba a bada shawarar yin amfani da miyagun ƙwayoyi Rosucard ® tare da masu hana kwayar cutar HIV kariya ba.

Cutar kuturta

Lokacin amfani da wasu mutum-mutumi, musamman na dogon lokaci, an samu rahoton yaɗuwar cutar cututtukan huhun da ke tsakanin su. Bayyananniyar cutar na iya haɗawa da gajeruwar numfashi, tari, mara amfani, da kuma wadatarwa gaba ɗaya (rauni, nauyi, da zazzabi). Idan kuna zargin wata cutar huhun ƙwayar cuta a cikin mahaɗa, to ya zama dole a dakatar da jiyya tare da Rosucard ®.

Type 2 ciwon sukari

Magungunan Statin na iya haifar da karuwa a cikin taro glucose na jini. A cikin wasu marasa lafiya da ke da haɗarin haɓakar ciwon sukari na mellitus, irin waɗannan canje-canjen na iya haifar da bayyanuwarsa, wanda hakan alama ce don alƙawarin cututtukan cututtukan zuciya. Koyaya, rage haɗarin cututtukan jijiyoyin bugun daji tare da statins yana ƙara haɗarin haɓakar ciwon sukari mellitus, sabili da haka, wannan lamarin bai kamata ya zama tushen tushen soke aikin jiyya ba. Marasa lafiya da ke cikin haɗari (maida hankali ne a cikin ƙwayar glucose na jini na 5.6-6.9 mmol / L, BMI> 30 kg / m 2, tarihin hauhawar jini, tarihin hauhawar jijiya) ya kamata a sa ido tare da kula da sigogin ƙirar ƙwayoyin cuta a kai a kai.

Bai kamata a yi amfani da Rosucard ® a cikin marasa lafiya da ƙarancin lactase, rashin haƙuri a cikin galactose da ƙwaƙwalwar glucose-galactose malabsorption.

A yayin nazarin karafan likitanci tsakanin marasa lafiyar Sinawa da Jafananci, an lura da karuwa a cikin tsari na rosuvastatin idan aka kwatanta da alamu da aka samu a tsakanin marasa lafiya na tseren Caucasian.

Tasiri kan ikon tuka motoci da hanyoyin sarrafa abubuwa

Yakamata a yi taka tsantsan yayin tuki motoci da ayyukan da ke buƙatar karuwar hankali da saurin halayen psychomotor (ƙaiƙayi na iya faruwa a lokacin jiyya).

Yawan abin sama da ya kamata

Tare da gudanar da aikin kai-tsaye na yawancin allurai na yau da kullun, sigogi na pharmacokinetic na rosuvastatin ba su canzawa.

Jiyya: babu takamaiman magani, ana amfani da maganin tawaya don magance ayyukan gabobin jiki da tsarinsu. Wajibi ne a lura da alamun ayyukan hanta da aikin CPK. Hemodialysis ba shi da tasiri.

Hulɗa da ƙwayoyi

Sakamakon wasu kwayoyi a kan rosuvastatin

Masu kare lafiyar sunadaran sufuri: rosuvastatin yana ɗaure wa wasu sunadarai na sufuri, musamman OATP1B1 da BCRP.Amfani da magungunan da ke jigilar abubuwan hana furotin na iya haɗuwa tare da haɓakawa da tarawar rosuvastatin a cikin jini da haɓakar haɗarin kamuwa da cuta (duba tebur 3).

Sankarin: tare da amfani da rosuvastatin da cyclosporine a lokaci guda, Kungiyar ta AUC na rosuvastatin ta kasance sau 7 sama da yadda aka lura cikin masu sa kai na lafiya. Ba ya tasiri a cikin ƙwayar plasma na cyclosporine. Rosuvastatin yana cikin contraindicated a cikin marasa lafiya shan cyclosporine.

Masu kare lafiyar kwayar cutar HIV: kodayake ba a san ainihin hanyar ma'amala ba, haɗaɗɗen amfani da masu hana HIV kariya na iya haifar da ƙaruwa sosai a cikin bayyanar rosuvastatin (duba tebur 3). Nazarin pharmacokinetic game da amfani da rosuvastatin na lokaci daya a kashi 20 MG da haɗuwa mai haɗari wanda ya ƙunshi masu hana garkuwa da kwayar cutar HIV guda biyu (400 MG na lopinavir / 100 MG na ritonavir) a cikin masu sa kai na lafiya ya haifar da kusan sau biyu da ninka sau biyar a cikin AUC (_0-24) da C_max rosuvastatin, bi da bi. Saboda haka, ba a bada shawarar yin amfani da magungunan Rosucard ® da masu hana kwayar cutar ta HIV ba (duba jadawalin 3).

Gemfibrozil da sauran magunguna masu rage kiba: haɗewar amfani da rosuvastatin da gemfibrozil yana haifar da ƙaruwa sau biyu a cikin C_max da kuma AUC na rosuvastatin. Dangane da bayanai kan takamaiman ma'amala, ba a sa ran ma'amala tsakanin gwamnatoci da fenofibrate, hulɗar magunguna zai yiwu. Gemfibrozil, fenofibrate, sauran fibrates, da nicotinic acid a cikin rage yawan maganin lipid (fiye da 1 g / rana) suna kara haɗarin cutar ta hanyar amfani da inhibitors na HMG-CoA, mai yiwuwa saboda gaskiyar cewa zasu iya haifar da myopathy lokacin amfani dashi kamar yadda monotherapy. Yayin shan magunguna tare da gemfibrozil, fibrates, acid nicotinic a cikin rage ƙarancin lipid, ana ba da shawarar marasa lafiya wani kashi na farko na Rosucard ® 5 mg, kashi 40 MG shine contraindicated a cikin haɗin gwiwa tare da fibrates.

Fusidic acid: babu takamaiman karatu da aka gudanar akan hulɗa da magunguna na fusidic acid da rosuvastatin, amma akwai rahotannin dabam dabam game da shari'ar rhabdomyolysis.

Ezetimibe: amfani da miyagun ƙwayoyi na Rosucard ult a lokaci guda na 10 mg da ezetimibe a kashi 10 MG yana haɗuwa tare da karuwa a cikin AUC na rosuvastatin a cikin marasa lafiya tare da hypercholesterolemia (duba tebur 3). Ba shi yiwuwa a fitar da haɗarin haɗarin sakamako masu illa saboda hulɗa na Pharmododynamic tsakanin Rosucard drug da ezetimibe.

Kashiram: amfani da rosuvastatin da erythromycin yana haifar da raguwa a cikin AUC_(0-t) 20% rosuvastatin da C_max rosuvastatin 30%. Irin wannan hulɗar na iya faruwa sakamakon karuwar motsin hanji da ke faruwa ta hanyar ɗaukar erythromycin.

Antacids: amfani da rosuvastatin na lokaci guda da dakatarwar antacids wadanda ke dauke da aluminium ko magnesium hydroxide, yana haifar da raguwa a cikin ƙwayar plasma na rosuvastatin da kusan 50%. Ba a faɗi wannan tasirin idan an yi amfani da antacids awanni 2 bayan shan rosuvastatin. Ba a yi nazarin mahimmancin asibiti na wannan hulɗa ba.

Isoenzymes na tsarin cytochrome P450: A cikin bincike vivo da in vitro sun nuna cewa rosuvastatin ba mai hanawa bane kuma mai samar da cytochrome P450 isoenzymes. Bugu da kari, rosuvastatin gurbataccen abu ne na wadannan enzymes. Saboda haka, hulɗa na rosuvastatin tare da wasu kwayoyi a matakin na rayuwa wanda ya shafi cytochrome P450 isoenzymes ba a tsammanin. Babu wata muhimmiyar hulɗar asibiti tsakanin rosuvastatin da fluconazole (mai hana isoenzymes CYP2C9 da CYP3A4) da ketoconazole (mai hana isoenzymes CYP2A6 da CYP3A4).

Yin hulɗa tare da kwayoyi waɗanda ke buƙatar daidaita kashi na rosuvastatin (duba tebur 3)

Ya kamata a daidaita yawan ƙwayar rosuvastatin idan ya cancanta, yin amfani da shi tare da kwayoyi waɗanda ke kara bayyana rosuvastatin. Idan ana tsammanin karuwar haɗuwa na sau 2 ko sama da haka, kashi na farko na Rosucard ® ya zama 5 MG 1 lokaci / rana. Hakanan ya kamata ku daidaita matsakaicin adadin Rosucard daily kowace rana don ɗaukar fallasa rosuvastatin bai wuce wancan na kashi 40 na mg da aka ɗauka ba tare da gudanar da magunguna lokaci guda na magungunan da ke hulɗa tare da rosuvastatin. Misali, matsakaicin adadin rosuvastatin na yau da kullun tare da amfani da lokaci guda tare da gemfibrozil shine 20 mg (haɓakawa ta hanyar sau 1.9), tare da ritonavir / atazanavir - 10 MG (karuwa a cikin bayyanuwa shine sau 3.1).

Tebur 3. Sakamakon aikin kwantar da hankali a kan fallasa rosuvastatin (AUC, ana nuna bayanai a cikin saukowa) - sakamakon gwaji na asibiti da aka buga.

Gudanar da hanyoyin kwantar da hankali	Bayanin Rosuvastatin	Canjin AUC a cikin rosuvastatin
Cyclosporin 75-200 mg 2 sau / rana, watanni 6	10 MG 1 lokaci / rana, kwana 10	Girman 7.1x
Atazanavir 300 mg / ritonavir 100 MG 1 lokaci / rana, kwana 8	10 MG kashi daya	3.1x karuwa
Simeprevir 150 MG 1 lokaci / rana, kwana 7	10 MG kashi daya	Girman girma na 2.8x
Lopinavir 400 mg / ritonavir 100 MG 2 sau / rana, kwana 17	20 MG 1 lokaci / rana, kwana 7	2.1x karuwa
Clopidogrel 300 MG (ana amfani da kashi), sannan 75 MG bayan awa 24	20 MG guda daya kashi	2x karuwa
Gemfibrozil 600 MG 2 sau / rana, kwana 7	80 MG guda daya kashi	Girma 1.9x
Eltrombopag 75 MG 1 lokaci / rana, kwana 10	10 MG kashi daya	1.6x girman kai
Darunavir 600 mg / ritonavir 100 MG 2 sau / rana, kwana 7	10 MG 1 lokaci / rana, kwana 7	1.5x girman kai
Tipranavir 500 MG / ritonavir 200 MG 2 sau / rana, kwana 11	10 MG kashi daya	Sau 1.4 yana ƙaruwa
Dronedarone 400 MG 2 sau / rana	Babu bayanai	Sau 1.4 yana ƙaruwa
Itraconazole 200 MG 1 lokaci / rana, 5 kwana	10 MG ko 80 MG sau ɗaya	Sau 1.4 yana ƙaruwa
Ezetimibe 10 MG 1 lokaci / rana, kwanaki 14	10 MG 1 lokaci / rana, kwana 14	1.2x karuwa
Fosamprenavir 700 MG / ritonavir 100 MG 2 sau / rana, kwana 8	10 MG kashi daya	Babu canzawa
Aleglitazar 0.3 MG, kwana 7	40 MG, kwana 7	Babu canzawa
Silymarin 140 MG sau 3 / rana, 5 kwana	10 MG kashi daya	Babu canzawa
Fenofibrate 67 MG sau 3 / rana, kwana 7	10 MG, kwana 7	Babu canzawa
Rifampin 450 MG 1 lokaci / rana, 7 kwana	20 MG guda daya kashi	Babu canzawa
Ketoconazole 200 MG 2 sau / rana, kwana 7	80 MG guda daya kashi	Babu canzawa
Fluconazole 200 MG 1 lokaci / rana, kwana 11	80 MG guda daya kashi	Babu canzawa
Erythromycin 500 MG sau 4 / rana, kwana 7	80 MG guda daya kashi	28% raguwa
Baikalin 50 MG sau 3 / rana, kwana 14	20 MG guda daya kashi	47% raguwa

Tasirin rosuvastatin akan sauran kwayoyi

Antioxists na Vitamin K: farawa rosuvastatin far ko kara yawan rosuvastatin a cikin marassa lafiya da ke karbar antagonists na bitamin a lokaci guda (alal misali, warfarin ko wasu maganin anticoagulants coumarin) na iya haifar da karuwa a INR. Canzawa ko ragewa kashi na Rosucard ® na iya haifar da raguwa a cikin INR. A irin waɗannan halayen, ana bada shawarar sarrafa INR.

Na maganin hana haihuwa / maganin maye gurbin maganin:yin amfani da rosuvastatin da na hana haihuwa na zamani yana kara AUC na ethinyl estradiol da AUC na norgestrel da 26% da 34%, bi da bi. Irin wannan karuwa a cikin ƙwayar plasma ya kamata a la'akari yayin zaɓin sashi na maganin hana haihuwa.

Babu bayanai game da magunguna akan amfani da rosuvastatin da maganin sauyawa. Ba za a iya raba irin wannan sakamako ba tare da yin amfani da rosuvastatin na lokaci daya da kuma maganin maye gurbin jiyya. Koyaya, wannan haɗin an yi amfani dashi sosai yayin gwaji na asibiti kuma haƙuri yana da haƙuri sosai.

Sauran magunguna: Babu wata muhimmiyar hulɗa ta rosuvastatin tare da digoxin ana tsammanin.

Magunguna da magunguna

Rosucard yana cikin rukunin gumaka. Yana hanawa HMG-CoA reductase - enzyme da ke juyawa GMG-CoA a mevalonate.

Bugu da kari, wannan kayan aikin yana kara adadin Masu karɓa LDL a kunne hepatocyteswanda ke kara karfin catabolism da kamawa LDL kuma yana haifar da hanawa VLDLrage gabaɗaya VLDL da LDL. Magungunan yana rage taro HS-LDL, babban yawan non-lipoprotein cholesterol, HS-VLDLP, TG, ykn basnpoprotein B, TG-VLDLP, jimla xc, kuma yana kara yawan abun cikin ApoA-1 da HS-HDL. Bugu da kari, yana rage rabo ApoVda ApoA-1, HS-ba HDL da HS-HDL, HS-LDL da HS-HDL, jimla xc da HS-HDL.

Babban tasiri na Rosucard yana daidai gwargwado daidai gwargwado. Ana iya ganin tasirin warkewa bayan farawar magani bayan mako guda, bayan kusan wata daya sai ya zama mafi girman, sannan kuma ya kara karfi ya zama dindindin.

An kafa mafi yawan abubuwan babban aiki a cikin plasma bayan sa'o'i 5. Cikakken bayani bioavailability ya zama 20%. Matsakaicin haɗin dangane da furotin jini na jini shine kusan 90%.

Tare da amfani na yau da kullun, magunguna ba su canzawa.

Mezazzabi Rosucard ta hanta. Penetrates da kyau shinge na jini. Babban metabolites – N-dismethyl da metabolites lactone.

Rabin rayuwar shine kusan awanni 19, alhali baya canzawa idan an kara yawan magunguna. Bayyanar Plasma a kan matsakaici - 50 l / h. Kusan 90% na kayan aiki ana cire su ta cikin hanji ba su canzawa ba, sauran ta hanyar kodan.

Yin jima'i da tsufa ba su shafar magunguna na Rosucard ba. Koyaya, ya dogara da tsere. Indiyawan suna da fifitawa da matsakaita Auc 1.3 sau sama da na tseren Caucasian. Auca cikin mutane na Mongoloid tseren, sau 2 more.

Alamu don amfani Rosucard

Alamu don amfanin Rosucard kamar haka:

na farko hypercholesterolemia ko gauraye dyslipidemia - ana amfani da miyagun ƙwayoyi azaman ƙari ga abinci idan abinci mai gina jiki shi kaɗai bai isa ba,
da bukatar rage girman ci gaba atherosclerosis - Ana amfani da miyagun ƙwayoyi azaman ƙarin kayan abinci a zaman wani ɓangare na jiyya don rage matakan jimlar cholesterol da Cholesterol to al'ada farashin
dangi Sinadarin hypercholesterolemia - ana amfani da maganin azaman ƙari ga abincin ko kuma azaman kayan haɗin abinci rage lipid far
da bukatar rigakafin rikice-rikice a cikin tsarin jijiyoyin zuciya tare da haɗarin faruwar hakanatherosclerotic cututtukan zuciya - ana amfani da maganin a matsayin wani ɓangaren warkarwa.

Side effects

Rashin halayen daga amfani da miyagun ƙwayoyi na iya zama kamar haka:

tsarin juyayi: ciwon kai, cutar asthenic, tsananin farin ciki,
tsarin numfashi: tari, dyspnea,
tsarin musculoskeletal: myalgia,
fata da ƙananan nama: na ciki edema, Stevens-Johnson ciwo,
alamomin dakin gwaje-gwaje: ƙarancin lokaci na aiki magani CPK dangane da sashi
halayen rashin lafiyan halayen: itching, cututtukan mahaifakurji
tsarin narkewa: tashin zuciya, jin zafi a ciki, maƙarƙashiyaamai zawo,
Tsarin endocrine: nau'in ciwon sukari na II,
tsarin urinary: proteinuriaurinary fili cututtuka.

A lokuta da wuya, zai yiwu na gefe neuropathy, maganin ciwon huhuƙwaƙwalwar ƙwaƙwalwar ajiyahepatitis, jaundice, ciwon kai, rhabdomyolysis, angioedema, hematuria, na lokaci karuwa AST aiki da ALT.

Haɗa kai

Sankarini a hade tare da rosucard yana ƙara darajar ta Auc kusan sau 7. Ba da shawarar shan fiye da 5 MG.

Gemfibrozilda sauransu ragewan lipid magunguna a hade tare da rosucard yana haifar da karuwa a cikin mafi girman taro da Auc kusan sau biyu. Hadarin myopathies. Matsakaicin adadin yayin haɗuwa tare Gemfibrozil - 20 MG. Lokacin hulɗa da zaren wuta ba a yarda da sashi na miyagun ƙwayoyi a 40 MG ba, kashi na farko shine 5 MG.

Hulɗa da miyagun ƙwayoyi tare da masu hana masu kariya na iya karuwa fallasawa Rosuvastatin. Ba'a bada shawarar amfani da wannan haɗin ba Cutar kanjamau ga marasa lafiya.

Hadawa Amaryaw kuma rosucard yana ragewa Aucna ƙarshen by 20%, kuma matsakaicin maida hankali - by 30%.

A yayin hada wannan magani da Lopinavir kuma ritonavir yana ƙaruwa da daidaitawa Auc kuma mafi girman maida hankali.

Antioxists na Vitamin K lokacin hulɗa tare da rosucard yana haifar da ƙaruwa daidaitaccen dangantakar ƙasa da ƙasa.

Ezetimibe lokaci guda tare da rosuvastatin na iya haifar da sakamako masu illa.

Antacid magunguna tare da aluminum hydroxide ko magnesium yana rage adadin maganin a jikin mutum da rabi. Don haka tsakanin liyafar da kuke buƙatar ɗaukar hutu aƙalla 2 hours.

Lokacin da hada Rosucard tare da maganin hana haihuwa yana nufin buƙatar sarrafa yanayin marasa lafiya.

Ra'ayoyi game da Rosucard

Reviews game da Rosucard galibi tabbatacce ne. Likitocin ne ke ba da shawarar wannan kayan aiki. Yana da sauƙin araha, don haka siyan sayan kai tsaye ne. Wadanda suka riga sun sha magani tare da wannan magani sun bar sake dubawa game da Rosucard, wanda aka ruwaito cewa maganin ya taimaka musu su kula da matakan cholesterol na al'ada kuma sun dakatar da ci gaba da cutar.

Farashin Rosucard

Farashin Rosucard yana da araha sosai idan aka kwatanta da yawancin analogues. Matsakaicin farashin maganin yana dogara da abubuwan da ke aiki a cikin allunan. Don haka, farashin 10 mg rosucard a cikin kunshin tare da faranti 3 kusan 500 rubles ne a Rasha ko hryvnias 100 a Ukraine. Kuma farashin Rosucard 20 MG a cikin kunshin tare da faranti 3 kusan 640 rubles ne a Rasha ko hryvnias 150 a Ukraine.

Kayan magunguna

Sashin aiki mai aiki a cikin shirin Rosucard, rosuvastatin, yana da kaddarorin don hana ayyukan rage aiki, da rage haɓakar ƙwayoyin mevalonate, wanda ke da alhakin haɗin cholesterol a farkon matakan a cikin ƙwayoyin hanta.

Wannan magani yana da tasirin maganin warkewa a cikin lipoproteins, yana rage haɗuwarsu ta ƙwayoyin hanta, wanda ke rage girman ƙwayar lipoproteins mara nauyi na jini kuma yana ƙaruwa da haɗuwa da ƙwayoyin lipoproteins masu yawa.

Pharmacokinetics na miyagun ƙwayoyi Rosucard:

Mafi girman abubuwan aiki a cikin abubuwan jini na jini, bayan shan allunan, suna faruwa ne bayan sa'o'i 5,
A bioavailability na miyagun ƙwayoyi shine 20.0%,
Bayyanar Rosucard a cikin tsarin ya dogara da karuwar sashi,
90.0% na Rosucard magani yana ɗaure ga furotin na plasma, mafi yawan lokuta, shine furotin albumin,
Metabolism na miyagun ƙwayoyi a cikin ƙwayoyin hanta a matakin farko shine kusan kashi 10,0%,
Don cytochrome isoenzyme A'a. P450, aiki mai aiki na rosuvastatin yana canzawa,
An cire maganin da 90.0% tare da feces, ƙwayoyin hanji suna da alhakin shi,
10.0 an ware shi ta amfani da sel koda tare da fitsari,
Magungunan magunguna na Rosucard ba su dogara da nau'in shekarun masu haƙuri ba, har ma da jinsi. Magungunan suna aiki daidai, duka a jikin saurayi da tsofaffi, kawai a cikin tsufa kawai yakamata ya zama mafi ƙarancin ƙwayar magani don lura da ƙayyadaddun ƙwayar cholesterol a cikin jini.

Ana iya jin tasirin warkewar farko na miyagun ƙwayoyi na rukunin rukunin Rosucard bayan shan miyagun ƙwayoyi na kwanaki 7. Ana iya ganin tasirin cutar lokacin ɗaukar kwayar na tsawon kwanaki 14.

Kudin maganin Rosucard ya dogara ne da masu kirkirar maganin, ƙasar da aka yi maganin. Analogues na Rashan na miyagun ƙwayoyi suna da rahusa, amma tasirin magani bai dogara da farashin maganin ba.

Rikicin Rasha na Rosucard, kamar yadda ya rage ƙididdigar a cikin cholesterol na jini, har da magungunan kasashen waje.

Farashin magungunan Rosucard a cikin Tarayyar Rasha:

Farashin rosucard 10.0 MG (Allunan 30) - 550,00 rubles,
Magungunan Rosucard 10.0 MG (90 inji mai kwakwalwa.) - 1540.00 rubles,
Magunguna na asali Rosucard 20.0 MG. (30 tab.) - 860.00 rubles.

Rayuwar shiryayye da amfanin allunan Rosucard shekara guda ne daga ranar da aka sake su. Bayan ranar karewa, magani ya fi kyau kar a sha.

Farashin Rosucard a cikin magunguna na Moscow

kwayoyin hana daukar ciki	10 MG	30 inji mai kwakwalwa	≈ 625 rub.
	10 MG	60 inji mai kwakwalwa.	≈ 1070 rub.
	10 MG	90 inji mai kwakwalwa.	≈ 1468 rub.
	20 MG	30 inji mai kwakwalwa	≈ 918 rub.
	20 MG	60 inji mai kwakwalwa.	≈ 1570 rub.
	20 MG	90 inji mai kwakwalwa.	≈ 2194.5 rub.
	40 MG	30 inji mai kwakwalwa	≈ 1125 rub.
	40 MG	90 inji mai kwakwalwa.	≈ 2824 rub.

Likitoci suna bita game da rosacea

Rating 3.3 / 5

Tasiri

Farashi / inganci

Side effects

Kyakkyawan analog na asalin Czech, wanda aka yi daga kayan ingancin albarkatun ƙasa, ya nuna kyakkyawan sakamako na asibiti.

A matsayinka na mai mulkin, rosuvastatin ba a yarda da farashin ba, kuma wannan yanayin ba togiya, rashin alheri.

Magungunan yana aiki da gaske, yana da amfani kawai bayan tuntuɓar ƙwararrun masani.

Rating 3.8 / 5

Tasiri

Farashi / inganci

Side effects

Ta yaba da ingancin wannan magani na kwayar cuta - yana daidaita metabolism mai narkewa sosai tare da ƙananan rikice-rikice da hanyoyin rashin tsayayye, ƙari - wannan ba shakka farashin ne, idan aka kwatanta da gicciye.

Akwai sakamako masu illa, amma ba kasafai ake lura dashi ba, saboda na rubuto shi sau da yawa tare da ƙaramin keta - allurai aƙalla 5-10 mg.

Rating 2.5 / 5

Tasiri

Farashi / inganci

Side effects

Amma game da isa ga mutum-mutumi: gumaka ba magunguna ne masu arha ba. Amma suna cikin waɗannan fewan ƙwayoyi waɗanda ke ceton rayuka da gaske. Tabbas, tare da caveat - ceci rayukan waɗanda ke da cututtukan da ke da alaƙa da atherosclerosis - infarction myocardial, angina pectoris, atherosclerosis na arteries na ƙananan ƙarshen. Idan sittin yakai 100-200 rubles, ina jin tsoron rubuto shi.

Yawancin ƙwayoyin halitta (kwafi da aka sake bugawa) na statins, amma, ba shakka, ba dukansu suna da tasiri daidai ba. Likitan da ke da alhakin likita zai ba da waɗannan ƙwayoyin ne kawai waɗanda akwai ingantattun bayanai daga nazarin kan daidaitawar warkewa tare da ƙwayar asali (a cikin yanayinmu, giciye ne). Ma'aikatan kantin magani a cikin waɗannan batutuwan, a matsayinka na doka, ba a karkatar da su gaba ɗaya kuma suna tambayarsu game da wani “musanyawa”, kazalika da yin amfani da shawarwarinsu a kan “madadin”, hanya ce ta zuwa mai yiwuwa rashin jin daɗin jiyya.

Rukunin Masu haƙuri na Rosucard

Ban sani ba yadda bai haifar da sakamako masu illa ga dangin ku ba. Rosucard kawai abin ban mamaki ne. Ni da miji nan da nan bayan shan wannan magani mun fara zawo, ɗan lokaci kaɗan, rashin bacci da kuma sabon abu mai ban mamaki tare da zuciyar da aka haɗa. Sabili da haka, yanzu zamu yanke shawara tare da likita game da makomar shigarwar.

Na sayi Rosucard akan 508 rubles. Na sha wata daya bayan kwana guda, cholesterol ya ragu daga 7 zuwa 4.6. Ban sha ba kuma bayan watanni 2 6.8. Na yi tsayayya da dogon lokaci, amma na yanke shawara: Zan sha. Na gwada ganye daban-daban, na sha atherocliphite, ba shi da wani tasiri.

"Farashin mai araha ne -" 900 re (!?) Wannan araha ce. Na fahimci cewa a nan za ku ga ana kulawa da wasu miliyoyi.

Rosucard magani ne mai kyau. Na sanya likitana ga kakata don rigakafin. Magungunan sun nuna sakamako bayan kusan 1 watan amfani. A cikin yanayinmu, yana da mahimmanci cewa ana iya ɗaukar rosucard tare da wasu magunguna. Ta ji jiki sosai kuma, mafi mahimmanci, babu cutarwa. Ba mu lura da wani aibu ba.

Kakana (shekaru 72) yana da matsalolin zuciya har tsawon shekaru goma, tabbas. Dangane da lalacewar, mun je wurin likitan zuciya, wanda ya shawarce mu da mu fara shan rosacea. Farashi mai araha ne, muna shayar da shi watan uku. Af, a kan sarrafa gudummawar jini, cholesterol ya ragu sosai. Muna farin ciki tare da rosacea!

Short Short

Rosucard (sashi mai aiki - rosuvastatin) - ƙwayar lipid ta rage daga rukuni na statins. A yau, kusan kashi 80 - 95% na marasa lafiya da ke fama da cututtukan zuciya (idan muka dauki kasashe masu tasowa) suna dauke da siffofin mutum. Irin wannan sanannen sanannen rukuni na wannan rukuni na kwayoyi yana nuna cikakken amincewa da shi ta hanyar likitocin zuciya, wanda ya kamata a yi la’akari da shi gaba ɗaya: a cikin 'yan shekarun nan, an gabatar da sakamakon gwaji na asibiti da yawa a gaban ƙungiyar likitocin, yana tabbatar da tabbataccen raguwar mace-macen ƙwaƙwalwa yayin jiyya tare da statins. Bugu da ƙari, ƙarin sakamakon waɗannan kwayoyi, waɗanda ke da isasshen wadatar kansu, an bayyana su: alal misali, tasirin anti-ischemic. Kuma tasirin anti-mai kumburi na statins yana da alaƙa da cewa wasu likitocin sun riga sun yi kokarin magance cututtukan arthritis da su. Rosucard magani ne cikakke daga ƙungiyar statin, an yarda dashi don amfani dashi a farkon shekarun 2000 na karni na ƙarshe. Duk da gasar daga wasu nau'ikan mutum biyar a kasuwar magunguna a yau, rosucard yana daya daga cikin (idan ba haka ba) mafi shahararrun magunguna a cikin wannan rukunin dangane da haɓakar haɓaka yawan adadin magungunan likita. Bayan shan kashi ɗaya na miyagun ƙwayoyi, ana lura da ganiya a cikin ƙwayar plasma bayan kimanin awa 5. Rosucard yana da tsawon rayuwa tsawon rai na tsawon awanni 19. Abubuwan da ke cikin pharmacokinetic na miyagun ƙwayoyi ba su da alaƙa da abubuwan kamar shekaru, jinsi, digiri na cikawar hanji, kasancewar hanta gajiya (ban da nau'ikansa mai tsanani). Kwayoyin rosuvastatin - abu mai aiki na miyagun ƙwayoyi - hydrophilic ne, yana haifar da ƙarancin tasirin sa ga kwayar cholesterol a cikin ƙwayoyin tsokoki na kasusuwa. Saboda wannan, rosucard ba shi da wata illa da za a iya amfani da ita a wasu siffofin. Wata hanyar amfani da miyagun ƙwayoyi akan "abokan aiki" a cikin rukunin magunguna (da farko akan atorvastatin da simvastatin) shine cewa kusan ba shi da amsa tare da enzymes na cytochrome P450 tsarin, wanda ke ba da izinin rosucard tare da sauran magunguna masu yawa (rigakafi, antihistamines, magungunan antiulcer, jami'in antifungal, da sauransu.

e.) ba tare da haɗarin hulɗar da ba'a so ba. An yi nazarin ingancin rosuvastatin (rosucard) kuma ana yin nazari a yawancin gwaji na asibiti. Daga cikin adadin karatun da aka kammala har zuwa yau, binciken MERCURY, wanda ya nuna babbar fa'idar wannan magani akan wasu siffofin ta hanyar tasirinsa akan bayanan lipid, yana da matukar amfani. Matsayin maƙasudin cholesterol "mara kyau" (LDL) lokacin da aka sami ƙwayar rosucard a cikin kashi 86% na marasa lafiya (ta yin amfani da kashi ɗaya na atorvastatin ya ba da sakamakon da ake so a cikin kawai 80%). A lokaci guda, matakin “mai kyau” cholesterol (HDL) ya yi matukar ƙaruwa fiye da lokacin amfani da atorvastatin. Rage yawan tattara ƙwayoyin atherogenic cholesterol (da farko LDL) ba shine maƙasudin burin maganin rage ƙwayar lipid ba. Hakanan yakamata ayi niyya don haɓaka abubuwan da ke cikin ƙananan ƙwayoyin cuta na HDL lipoproteins, matakin wanda, a matsayin mai mulkin, ya ragu. Kuma rosucard ya sami nasarar magance wannan: sakamakon tasirin sa na lipoproteins, shima ya wuce simvastatin da pravastatin. Zuwa yau, ana bada shawarar yin amfani da maganin a cikin kashi 10-40 MG kowace rana.

Amintaccen magani shine ƙarancin mahimmanci game da shi fiye da aminci, musamman idan an yi nufin maganin ne don yawancin marasa lafiya. An ba da kulawa sosai game da batun aminci na statin ta halin da ake ciki tare da cerivastatin, wanda aka cire shi daga kasuwa saboda yawan sakamako masu illa. A wannan batun, rosuvastatin (rosucard) an gudanar da bincike mai zurfi dangane da bayanan amincinsa. Kuma, kamar yadda aka tabbatar yayin gwaji na asibiti, haɗarin sakamako masu illa yayin ɗaukar miyagun ƙwayoyi (batun layin da aka ba da shawarar) ba shi da girma fiye da ragowar gumakan da ake amfani da su a halin yanzu.

Pharmacology

Magungunan ƙwayar cuta daga rukunin gumakan. Zabi mai hana ingila na HMG-CoA reductase, mai samar da enzyme wanda ke canza HMG-CoA zuwa mevalonate, mai keratin cholesterol (Ch).

Theara yawan masu karɓar LDL a saman hepatocytes, wanda ke haifar da karuwar haɓakawa da catabolism na LDL, hanawar haɗakar VLDL, rage yawan haɗakar LDL da VLDL. Rage yawan taro na LDL-C, HDL cholesterol-non-lipoproteins (HDL-non-HDL), HDL-V, cikakken cholesterol, TG, TG-VLDL, apolipoprotein B (ApoV), rage yawan rabo daga LDL-C / LDL-C, jimlar - HDL, Chs-not HDL / Chs-HDL, ApoV / apolipoprotein A-1 (ApoA-1), yana ƙara yawan haɗuwar Chs-HDL da ApoA-1.

Sakamakon rage ƙwayar lipid shine gwargwadon kai tsaye zuwa yawan adadin da aka tsara. Tasirin warkewa yana bayyana a cikin mako 1 bayan farawar, bayan makonni 2 ya kai 90% na matsakaicin, ya kai matsakaicin har zuwa makonni 4 sannan kuma ya kasance koyaushe. Magungunan yana da inganci a cikin marasa lafiyar manya tare da hypercholesterolemia tare da ko ba tare da hypertriglyceridemia (ba tare da la'akari da launin fata, jinsi ko shekaru), ciki har da a cikin marasa lafiya da ciwon sukari mellitus da familial hypercholesterolemia. A cikin 80% na marasa lafiya tare da nau'in IIa da IIb hypercholesterolemia (rarrabuwa na Fredrickson) tare da matsakaicin farawa na LDL-C kusan kimanin 4.8 mmol / L, yayin ɗaukar ƙwayar a cikin kashi 10 mg, maida hankali ne LDL-C ya kai ƙasa da 3 mmol / L. A cikin marasa lafiya tare da hyzycholesterolemia na homozygous familial na karɓar maganin a kashi 20 MG da 40 MG, matsakaicin raguwa a cikin taro na LDL-C shine 22%.

Ana lura da sakamako mai ƙari a hade tare da fenofibrate (dangane da raguwa a cikin taro na TG kuma tare da nicotinic acid a cikin allurai mai rage ƙwaƙwalwar ƙwayar cuta (aƙalla 1 g / day) (dangane da raguwa a cikin maida hankali kan HDL-C).

Yadda za a ɗauki rosucard?

Ya kamata a ɗauka miyagun ƙwayoyi Rosucard a baki tare da isasshen adadin ruwa. An haramta tauna kwamfutar hannu, saboda ana hade shi da membrane wanda ke narkewa a cikin hanjin.

Kafin fara karatun warkewa tare da magungunan Rosucard, dole ne mai haƙuri ya bi abincin anticholesterol, kuma dole ne abincin ya bi tsarin duka tare da statins, gwargwadon sashi mai aiki - rosuvastatin.

Likita ya zaɓi zaɓi daban-daban ga kowane mara lafiya, gwargwadon sakamakon gwaje-gwajen gwaje-gwaje, da kuma haƙurin mutum na jikin mai haƙuri.

Likita ne kawai, idan ya cancanta, ya san yadda ake maye gurbin allunan Rosucard. Gyaran gyaran ƙwayar cuta da maye gurbin miyagun ƙwayoyi tare da wani magani yana faruwa ba a cikin makonni biyu ba daga lokacin gudanarwa.

Maganin farko na maganin Rosucard bai kamata ya wuce milligram 10.0 ba (kwamfutar hannu ɗaya) sau ɗaya a rana.

A hankali, a cikin aikin jiyya, idan ya cancanta, a cikin kwanaki 30, likita ya yanke shawarar ƙara yawan sashi.

Don haɓaka kullun na maganin Rosucard, ana buƙatar waɗannan dalilai masu zuwa:

Wani mummunan nau'in hypercholesterolemia, wanda ke buƙatar matsakaicin sashi na 40,0 milligrams,
Idan a ma'aunin milligram na 10.0, lipogram ya nuna raguwar cholesterol. Likita ya kara sashi na 20,0 milligram, ko kuma nan da nan kaso mafi yawa,
Tare da matsanancin rikicewar bugun zuciya,
Tare da wani babban ci gaba na ilimin halayyar cuta, atherosclerosis.

Wasu marasa lafiya, kafin kara yawan sashi, suna buƙatar yanayi na musamman:

Idan alamun cututtukan hanta sun dace da ma'aunin Yara-Pugh na maki 7.0, to ba a bada shawarar sashi na Rosucard ba,
Game da gazawar koda, zaku iya fara karatun magani tare da allunan 0.5 a kowace rana, kuma bayan hakan zaku iya ƙara yawan sashi zuwa milligram 20,0, ko ma zuwa sigar matsakaicin,
A cikin gaɓar ƙwayar ƙwayar cuta na koda, ba a yarda da statins,
Matsakaici mai rauni na gawar koda. Matsakaicin adadin magungunan Rosucard ba likitoci ne suka umarta ba,
Idan akwai haɗarin ƙwayar cuta, myopathy kuma yana buƙatar farawa tare da Allunan 0.5 kuma an haramta yawan kashi 40.0 milligrams.

Yin gyare-gyare a jiki yayin maganiga abinda ke ciki ↑

Kammalawa

Za'a iya amfani da magani na Rosucard a cikin magance ƙwayar cholesterol a cikin jini, kawai a hade tare da abinci mai gina jiki na anticholesterol.

Rashin bin tsarin abincin zai jinkirta tsarin warkarwa kuma ya lalata mummunan tasirin miyagun ƙwayoyi a jiki.

Ba za a iya amfani da miyagun ƙwayoyi Rosucard a matsayin magani na kansa ba, kuma lokacin da aka tsara shi an hana shi da daidaituwa don daidaita matakan allunan, kazalika da canza tsarin kulawa.

Yuri, dan shekara 50, Kaliningrad: statins sun rage mini cholesterol a al'ada cikin makonni uku. Amma bayan wannan, lissafin ya sake tashi, kuma dole in sake yin magani tare da kwayoyin maganin statin.

Sai kawai lokacin da likita ya canza magunguna na baya zuwa Rosucard, Na lura cewa waɗannan kwayoyin ba kawai zasu iya dawo da cholesterol na al'ada ba, har ma ba su ƙara shi sosai ba bayan hanya ta warke.

Natalia, 57 years old, Ekaterinburg: cholesterol ya fara tashi yayin haila, kuma abincin ba zai iya rage shi ba. Na kasance ina shan kwayoyi masu amfani da rosuvastatin tsawon shekaru 2. Wata 3 da suka wuce, likita ya maye gurbin magunguna na baya tare da allunan Rosucard.

Na ji tasirinsa nan da nan - Na ji daɗi kuma nayi mamakin cewa na iya rasa kilo 4 na wuce nauyi.

Nesterenko N.A., likitan zuciya, Novosibirsk - Ina wajabta gumaka don marasa lafiya na kawai lokacin da aka gwada dukkan hanyoyin rage cholesterol kuma akwai babban hadarin bunkasa cututtukan zuciya, da kuma atherosclerosis.

Statins suna da yawa sakamako masu illa ga jiki, wanda ke shafar ingancin rayuwar marasa lafiya.

Amma ta yin amfani da magungunan Rosucard a cikin al'ada, Na lura cewa marasa lafiya sun daina gunaguni game da mummunan tasirin da ke tattare da statins. Yarda da duk shawarwari don amfani zai samar wa mara lafiya da mafi ƙarancin halayen jiki.